- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02928536
The TackSHS Survey: a Pan-European Study on SHS
The TackSHS Survey: a Cross-sectional Study on Secondhand Smoke in 12 European Countries
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study characteristics The TackSHS survey is a face-to-face population-based cross-sectional survey that will be conducted in 12 selected European countries, coordinated by Dr Silvano Gallus, Department of Epidemiology of the "Mario Negri" Institute (Milan, Italy).
Background Exposure to secondhand smoke (SHS) has serious adverse health effects on adults and children, causing more than 600,000 deaths each year worldwide. Estimates of prevalence of non-smokers exposed to SHS range between 20% and 60% in various European countries. The WHO recommend to develop smoke-free policies to protect non-smokers from SHS exposure. E-cigarettes have irrupted in the market over the last 5 years, and their sales and popularity have considerably grown in the European Union (EU). Approximately 7% of Europeans ever used e-cigarettes. TackSHS is a new research project funded by the European Commission (EC) within the Horizon 2020 programme (grant agreement: 681040). Within the TackSHS Project, selected work packages (WP; i.e., WP3, WP9 and WP10) involve the conduction of a survey in 12 EU countries: the TackSHS survey.
Objectives Objectives of this cross-sectional study include: i) to estimate prevalence, and investigate individual-level and country-specific determinants, of smoking, e-cigarette use, and exposure to SHS and to e-cigarette aerosol in selected European countries (WP3); ii) to analyze the attitudes, perceptions and behaviours of the adult European population towards policies to limit SHS exposure (WP3); iii) to compare selected smoking-related data collected through the TackSHS survey with those from a companion pan-European survey conducted in 2010 (WP3); iv) to assess morbidity and mortality from selected respiratory and cardiovascular diseases attributable to SHS exposure among adults and children in the European population (WP9); v) to quantify the economic burden associated to the exposure to SHS and e-cigarette aerosol in Europe (WP10).
Methods The cross-sectional survey will be conducted in 12 European countries (Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania, and Spain), representing geographical, legislative and cultural variations across the EU. In each of the 12 selected countries, approximately 1000 individuals, representative of the general population aged 15 years and over will be enrolled. The final sample will therefore include a total of approximately 12,000 subjects. The sample size in each specific country will allow us to obtain prevalence estimates with a maximum standard error (SE) lower than ± 1.6%. Therefore, with such a sample size we will be able to provide stable prevalence estimates (with a relatively small 95% confidence interval), overall, but also in each specific country.
Survey participants will have to satisfy the following inclusion criteria: i) 15 years and over of age; ii) residence in one of the 12 selected countries; iii) ability to understand and answer the questions of the questionnaire of the study in the country-specific language; iv) formal acceptance to participate in the study.
The multi-stage methodology will be used as the preferred sampling methodology, but other methods, including stratified or simple sampling or quota methods, will also be accepted wherever it is not possible to conduct a multistage random sampling.
Participants will be surveyed by trained interviewers through face-to-face interviews using a structured standardized questionnaire, including information on: i) socio-economic and demographic characteristics; ii) cigarette smoking habit and e-cigarette use; iii) SHS and e-cigarette aerosol exposures in different sites; iv) attitudes and perceptions on smoke-free regulations. Whenever possible, data will be collected within computer assisted personal interviews (CAPI). Alternatively, paper and pencil (P&P) interviews will be accepted.
Once the fieldwork is completed, data will be checked for coherence and for the presence of possible errors, cleaned, and finalized into a single dataset by expert biostatisticians at the Department of Epidemiology of "Mario Negri" Institute.
According to the statistical analyses, within WP3 both univariate and multivariate (i.e., multiple logistic regression) analyses will be considered to identify sub-groups of the population or clusters of countries more frequently exposed to SHS or to passive exposure to emissions from e-cigarettes. Moreover, to evaluate the changes in time of selected smoking-related aspects, TackSHS data will be compared with data from a previous companion European survey (the PPACTE survey). Within WP9, through the use of specific algorithms, it will be possible to estimate attributable mortality and morbidity to SHS in Europe, taking advantage of: i) prevalence figures on tobacco smoking and SHS exposure from the ThackSHS survey and other selected European datasets; ii) morbidity and mortality figures from the WHO and other sources; iii) and the quantification of the association between SHS exposure and the risk of SHS-related diseases from scientific literature reviews. Within WP10, using SHS exposure figures from the TackSHS survey, a Return On Investment model will be developed to assess the cost-effectiveness, budget impact and a wider set of social return on investment metrics of selected policies aimed at reducing exposure to SHS across European countries.
Ethical Issues Although in EU countries, according to their current legislation, it is not mandatory for this type of studies (i.e., population-based cross-sectional survey) to obtain either a formal approval of the study protocol from ethics committees or the written consent signed by survey participants, following the request of the European Commission, we will satisfy these both these ethical requirements. Thus, after evaluation of the Italian Ethics Committee (i.e., the Ethics Committee of the study coordinator), the study protocol will be submitted for evaluation to the Ethics Committees of the other 11 countries where data will be collected. Moreover, formal consent (and signature in case of P&P interview) will be obtained from each adult participant, and, in case of minors from one of their parents or legal tutors. All data will be managed anonymously, in respect of the privacy regulations in force, only for scientific purposes, without any lucrative aim. These and other measures are in agreement with national and current or forthcoming EU (i.e., Directive 95/46/EC) regulations.
Relevance, implications and dissemination Thanks to the TackSHS survey, we will provide a characterization of exposure to SHS and to e-cigarette aerosol in populations with different socioeconomic level and from various European countries. We will also provide the first estimates of morbidity and mortality due to SHS exposure at the European level, and the cost impact of interventions to control SHS exposure through purpose-built economic models. The main findings of the TackSHS survey will be disseminated on international peer-reviewed open-access journals and on the TackSHS Project website (www.tackshs.eu), and will be presented in national or international conferences.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Milan, Italy, 20144
- DOXA Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
In each of the 12 selected European countries, approximately 1000 individuals, representative of the general population aged 15 years and over in terms of age, sex, geographic area, and socio-economic characteristics, will be enrolled in this cross-sectional study. The final sample will therefore include a total of approximately 12,000 subjects.
Sample size computation The sample size in each specific country will allow us to obtain prevalence estimates with a maximum standard error (SE) lower than ± 1.6%. Therefore, with such a sample size we will be able to provide stable prevalence estimates (with a relatively small 95% confidence interval), overall but also in each specific country.
Description
Inclusion Criteria:
- individuals aged 15 years and over;
- individuals resident of the 12 selected countries;
- individuals able to understand and answer the questions of the questionnaire of the study in the country-specific language;
- individuals who formally accept to participate in the study.
Exclusion Criteria:
No specific exclusion criteria are considered.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of Daily Exposure to Secondhand Smoke (SHS) in Indoor Settings
Time Frame: Baseline
|
Exposure to secondhand smoke (SHS) is assessed among non-smokers and indicates the general daily exposure (during a working day and during a non-working day) to SHS in indoor settings (i.e., at home, at workplace, in public and private transports and in other indoor settings).
SHS exposure is self-reported and is assessed through a face-to-face interview at baseline (thus representing current exposure at interview).
|
Baseline
|
Prevalence of Exposure to Secondhand Aerosol (SHA) From Electronic Cigarettes
Time Frame: Baseline
|
Exposure to secondhand aerosol (SHA) is assessed among electronic cigarette non-users and indicates the general daily exposure (during a working day and during a non-working day) to SHA in indoor settings (i.e., at home, at workplace, in public and private transports and in other indoor settings).
SHA exposure is self-reported and is assessed through a face-to-face interview at baseline (thus representing current exposure at interview).
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of Never, Current and Former Smokers
Time Frame: Baseline
|
Cigarette consumption is assessed at baseline (thus representing current use at interview) through self-reported questions on lifetime use.
Never smokers were defined as participants who had never smoked or had smoked less than 100 cigarettes in their lifetime.
Smokers were defined as participants who reported smoking at least 100 cigarettes (including hand-rolled cigarettes) during their lifetime.
Current smokers were smokers who reported smoking at the time they participated in this survey, while former smokers were smokers who stopped smoking by the time they participated in this survey.
|
Baseline
|
Prevalence of Never, Current and Former Electronic Cigarette Users
Time Frame: Baseline
|
Electronic cigarette use is assessed at baseline (thus representing current use at interview) through self-reported questions on lifetime use.
Current electronic cigarette users were defined as those who reported using the electronic cigarette occasionally (5 days or less) or regularly (more than 5 days) in the last 30 days.
Former users of electronic cigarette were those who reported using it in the part but not over the last 30 days.
|
Baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Silvano Gallus, Sc.D, Istituto Di Ricerche Farmacologiche Mario Negri
Publications and helpful links
General Publications
- Fernandez E, Lopez MJ, Gallus S, Semple S, Clancy L, Behrakis P, Ruprecht A, Gorini G, Lopez-Nicolas A, Radu-Loghin C, Soriano JB; TackSHS Project Investigators; TackSHS Project Investigators. Tackling second-hand exposure to tobacco smoke and aerosols of electronic cigarettes: the TackSHS project protocol. Gac Sanit. 2020 Jan-Feb;34(1):77-82. doi: 10.1016/j.gaceta.2019.07.002. Epub 2019 Sep 23.
- Amalia B, Liu X, Lugo A, Fu M, Odone A, van den Brandt PA, Semple S, Clancy L, Soriano JB, Fernandez E, Gallus S; TackSHS Project Investigators. Exposure to secondhand aerosol of electronic cigarettes in indoor settings in 12 European countries: data from the TackSHS survey. Tob Control. 2021 Jan;30(1):49-56. doi: 10.1136/tobaccocontrol-2019-055376. Epub 2020 Mar 2.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 6895 (FHCRC/UW CC IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Second Hand Tobacco Smoke
-
Juul Labs, Inc.Inflamax Research IncorporatedCompletedSecond Hand Tobacco SmokeCanada
-
Institut Català d'OncologiaFondazione IRCCS Istituto Nazionale dei Tumori, Milano; University of Aberdeen and other collaboratorsUnknownSecond Hand Tobacco SmokeSpain
-
George Washington UniversityNot yet recruitingSecond Hand Tobacco SmokeUnited States
-
Duke Kunshan UniversityNational Natural Science Foundation of China; Fudan University; Taizhou Municipal...CompletedSecond Hand Tobacco SmokeChina
-
University of ArkansasCoalition for a Tobacco Free Arkansas; Tri-County Rural Health NetworkCompletedTobacco Use | Second Hand Tobacco SmokeUnited States
-
Institut Català d'OncologiaPublic Health Agency of Barcelona; Hellenic Cancer SocietyUnknownSecond Hand Tobacco SmokeGreece
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedTobacco Use Cessation | Second Hand Tobacco SmokeUnited States
-
University of RochesterNational Cancer Institute (NCI)CompletedTobacco Use Cessation | Second Hand Tobacco SmokeDominican Republic
-
Institut Català d'OncologiaFondazione IRCCS Istituto Nazionale dei Tumori, Milano; University of Aberdeen and other collaboratorsCompletedTobacco Use | Tobacco Smoking | Second Hand Tobacco Smoke
-
Harvard School of Public Health (HSPH)Truth InitiativeCompletedTobacco Use Cessation | Second Hand Tobacco Smoke
Clinical Trials on no intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
Case Western Reserve UniversityAmerican UniversityNot yet recruitingNutrition, Healthy
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown